SinghAKVidyadhariABhuraniD,et al.Effect of imatinib treatment on renal anaemia in chronic myeloid leukemia patients. J Oncol Pharm Pract2023. doi: 10781552231160113.
2.
LiuZShiYYanZ,et al.Impact of anemia on the outcomes of chronic phase chronic myeloid leukemia in TKI era. Hematology2020; 25: 181–185.
3.
CortesJO’BrienSQuintasA,et al.Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase. Cancer: Interdiscip Int J Am Cancer Soc2004; 100: 2396–2402.
4.
NairRRChauhanRHarankhedkarS,et al.Imatinib-induced platelet dysfunction and hypofibrinogenemia in chronic myeloid leukemia. Blood Coagul Fibrinolysis2019; 30: 246–248.
5.
LatagliataRVolpicelliPBrecciaM, et al.Incidence of persistent/late chronic anemia in newly diagnosed patients with chronic myeloid leukemia responsive to imatinib. Am J Hematol2015; 90: 105–108.
6.
SakuraiMKikuchiTKariganeD, et al.Renal dysfunction and anemia associated with long-term imatinib treatment in patients with chronic myelogenous leukemia. Int J Hematol2019; 109: 292–298.
7.
WaritWNorasetthadaLTantiworawitA, et al.High prevalence of platelet dysfunction among patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors. Blood2014; 124: 2781.
8.
AgisHJaegerEDoningerB, et al.In vivo effects of imatinib mesylate on human haematopoietic progenitor cells. Eur J Clin Investig2006; 36: 402–408.
9.
Barta VSUppal NNPullman JM, et al. Acute tubular injury associated with imatinib (Gleevec): A case report and review of the literature. J Onco-Nephrol 2017; 1: 57–61.
10.
MouraMSBenevidesTCDelamainMT, et al.Evaluation of anemia after long-term treatment with imatinib in chronic myeloid leukemia patients in chronic phase. Hematol, Transfus Cell Ther2019; 41: 329–334.
11.
YilmazMLahotiAO’BrienS, et al.Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. Cancer2015; 121: 3894–3904.
12.
GrubbANymanUBjörkJ. Improved estimation of glomerular filtration rate (GFR) by comparison of eGFRcystatin C and eGFRcreatinine. Scand J Clin Lab Invest2012; 72: 73–77.
